Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SI-BONE, Inc. (NASDAQ: SIBN) files a range of reports with the U.S. Securities and Exchange Commission that provide detailed insight into its sacropelvic-focused medical device business. This SEC filings page brings together those documents and pairs them with AI-powered summaries to help interpret the information that matters for SIBN stock.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, SI-BONE discloses its revenue from sacroiliac joint fusion and related sacropelvic procedures, gross margin, operating expenses, net loss, adjusted EBITDA, cash and investments, and other key financial metrics. These filings also describe risk factors, clinical evidence supporting its technologies, and considerations related to reimbursement, supply chain, and the healthcare operating environment.
Current reports on Form 8-K are used by SI-BONE to announce material events such as quarterly financial results, preliminary unaudited revenue and cash figures, and leadership or board changes. For example, recent 8-K filings have referenced press releases on quarterly results, preliminary full-year revenue, and executive transitions, as well as consulting and retirement agreements with senior leaders and directors.
This page also provides access to other SEC documents that may include registration statements and proxy materials, which can address topics such as equity compensation, board composition, and corporate governance. For investors interested in insider activity, Forms 3, 4, and 5 (when filed) detail transactions by directors and officers in SIBN shares.
AI-generated highlights on this platform are designed to make SI-BONE’s filings easier to navigate by surfacing key figures, summarizing management’s discussion of performance, and pointing to sections that discuss sacropelvic technologies, clinical evidence, and reimbursement dynamics. Real-time updates from EDGAR ensure that new 10-K, 10-Q, and 8-K filings for SI-BONE, Inc. are available promptly, while AI summaries help reduce the time required to understand their implications.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 3,057,039 shares of SI-BONE, Inc. common stock, representing 6.9% of the class. The filing shows sole voting power for 2,997,105 shares and sole dispositive power for 3,057,039 shares. The amendment is signed by Spencer Fleming, Managing Director on 04/24/2026.
SI-BONE, Inc. reported worldwide revenue of $200.9 million for fiscal 2025, representing an annual increase of approximately 20%. The company recorded a net loss of $18.9 million (an annual improvement of ~39%) and reported positive Adjusted EBITDA of $8.9 million. SI-BONE exited 2025 with $147.8 million in cash and equivalents and stated that more than 140,000 procedures have been performed worldwide since inception. The company highlighted commercial and regulatory progress, including launch of iFuse TORQ in Europe and a New Technology Add-on Payment (NTAP) for iFuse TORQ TNT effective October 1, 2025.
SI-BONE, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026. Investors will elect two directors (Jeffrey W. Dunn and John G. Freund, M.D.) to terms ending in 2029, ratify PricewaterhouseCoopers LLP as auditor for 2026, and cast an advisory say-on-pay vote on executive compensation.
Management highlights 2025 results including worldwide revenue of $200.9 million, about 20% growth, a net loss of $18.9 million with roughly 39% improvement, positive Adjusted EBITDA of $8.9 million versus a prior loss, and year-end cash and equivalents of $147.8 million.
SI-BONE, Inc. director Greg K. Hinckley exercised stock options to acquire 3,085 shares of common stock at an exercise price of $5.94 per share. Following the transaction, he directly owns 105,135 shares of common stock.
This direct holding figure includes 8,675 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock. A portion of the shares is held with his spouse as community property with right of survivorship. The option exercised was part of a grant that vested in equal monthly installments over three years beginning on October 17, 2018.
SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported selling 3,318 shares of common stock in two open-market transactions on April 2, 2026, at weighted average prices of $12.9228 and $12.8137 per share.
According to the footnotes, these sales were required to cover tax withholding obligations arising from the vesting of restricted stock units and were executed as "sell to cover" transactions, rather than discretionary trades. After these sales, Maheshwari directly owns 263,148 shares of SI-BONE common stock, including 193,458 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. senior vice president and chief legal officer Michael A. Pisetsky reported selling a total of 3,134 shares of common stock in open-market transactions on April 1–2, described as sales required to cover tax withholding on vesting restricted stock units under a “sell to cover” arrangement, rather than discretionary trades.
Sale prices ranged from about $12.55 to $13.09, with weighted averages around the reported prices. After these transactions, he holds 282,840 shares directly, which the disclosure states includes 151,034 shares issuable upon settlement of restricted stock units.
SI-BONE Inc amendment: The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting zero shares beneficially owned of SI-BONE Inc common stock, representing 0% of the class. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report ownership separately in reliance on SEC Release No. 34-39538.
SI-BONE, Inc. director Mika Nishimura reported an open-market sale of 4,100 shares of Common Stock. The shares were sold on March 12, 2026 at a weighted average price of $13.8293 per share, with individual trade prices ranging from $13.82 to $13.86.
After this transaction, Nishimura directly holds 32,716 shares of SI-BONE common stock. This figure includes 8,675 shares issuable upon settlement of restricted stock units, each of which represents a contingent right to receive one share of common stock. No option exercises or derivative transactions were reported.
SI-BONE, Inc. filed a shelf registration on February 24, 2026 to register an indefinite aggregate amount of securities for issuance and resale, to be offered from time to time after the effective date. The shelf covers common stock, preferred stock, debt securities and warrants, and contemplates both issuer and selling securityholder transactions.
The prospectus states the companys common stock trades on the Nasdaq Global Market under the symbol SIBN, with a reported last sale price of $15.62 on February 23, 2026. Terms, amounts, distribution methods and whether the company receives proceeds will be provided in future prospectus supplements.